Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Anavex Lf SC (NQ: AVXL )

6.775 +0.415 (+6.53%)
Streaming Delayed Price Updated: 3:09 PM EST, Nov 28, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Anavex Lf SC

< Previous 1 2 3 4 5 6 Next >
Crude Oil Falls; RedHill Biopharma Shares Spike Higher
U.S. stocks traded mixed toward the end of trading on Monday. The Dow traded down 0.13% to 35,344.56 while the NASDAQ rose 0.11% to 14,266.69. The S&P 500 also fell, dropping, 0.08% to 4,555.47. 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Why Anavex Life Sciences Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Anavex Life Sciences Corp. (NASDAQ: AVXL) moved lower during Monday’s session after the company reported fourth-quarter financial results. 
Via Benzinga
Wall Street Slumps As "Fear Gauge" Mounts Comeback
Wall Street is placing its four-week rally on hold, as investors watch the retail sector following an online record-setting Black Friday and await this week's slew of economic data. 
Via Talk Markets
Recap: Anavex Life Sciences Q4 Earnings
Via Benzinga
Anavex Stock Is Moving Higher Monday: What's Going On?
Anavex Life Sciences Corp (NASDAQ: AVXL) shares are trading higher Monday. 
Via Benzinga
Preview: Anavex Life Sciences's Earnings
Via Benzinga
The Latest Analyst Ratings for Anavex Life Sciences
Via Benzinga
Nasdaq Moves Higher; US New Home Sales Fall In October
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite moving higher on Monday. The Dow traded down 0.23% to 35,310.40 while the NASDAQ rose 0.21% to 14,280.12. The S&P 500 also... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why ReNew Energy Global Shares Are Trading Higher By Around 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of ReNew Energy Global Plc (NASDAQ: RNW) gained during Monday’s session following strong quarterly sales. ReNew Energy Global posted quarterly sales of $345.00 million, topping market estimates... 
Via Benzinga
General Dynamics, Microsoft, Waste Management And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded lower, with the Nasdaq Composite falling more than 1% on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Analyst Ratings for Anavex Life Sciences
Via Benzinga
This Short-Squeeze Candidate Could Actually Pan Out in the Long Run
Short-sellers have piled into this clinical-stage biopharma stock. 
Via The Motley Fool
Why Cutera Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Wednesday's Session
Gainers Tango Therapeutics, Inc. (NASDAQ: TNGX) climbed 85.2% to $7.09 after gaining 11% on Tuesday. Tango Therapeutics recently posted a narrower quarterly loss. 
Via Benzinga
Earnings Preview: Anavex Life Sciences
Via Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth $3,000 Today
Via Benzinga
Here's How Much $100 Invested In Anavex Life Sciences 5 Years Ago Would Be Worth Today
Via Benzinga
Akamai Technologies, Array Technologies Music, HNI, PENN Entertainment And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded lower, with the Nasdaq Composite falling around 100 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Anavex Life Sciences Releases Encouraging Long Term Data From Rett Syndrome Study
Anavex Life Sciences Corp (NASDAQ: AVXL) announced that long-term clinical study results from the U.S. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
What's Going On With Anavex Life Sciences Shares Today?
Anavex Life Sciences Corp (NASDAQ: AVXL) shares are trading higher Thursday after the company reported results from its Phase 2 study in patients with Parkinson's disease dementia showing beneficial... 
Via Benzinga
Wall Street Thinks This Small-Cap Stock Can Quadruple in Value
The company generates no revenue, but it may be worth taking a chance on as it possesses lots of upside. 
Via The Motley Fool
Why Shares of Anavex Life Sciences Rose 12.4% in February
The company's first-quarter earnings report detailed positive news regarding its pipeline. 
Via The Motley Fool
Is Anavex Life Sciences Stock a Buy Now?
A short squeeze could be a possibility if the company can prove that bearish investors are wrong about its business. 
Via The Motley Fool
Why Anavex Life Sciences Stock Bolted Higher in January
The biotech's shares have been steadily leaking higher following positive late-stage Alzheimer's disease trial results. 
Via The Motley Fool
Anavex Life Sciences Stock Shows Improved Price Strength Rating
Anavex Life Sciences stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, rising from 68 to 75. 
Via Investor's Business Daily
3 Biotech Stocks Under $15 Worth a Second Look in 2023
All three stocks have promising therapies that could drive revenue in the coming years. 
Via The Motley Fool
Top Picks For 2023: Anavex Life Sciences
Anavex is a biopharmaceutical company dedicated to the development of novel drug candidates to treat central nervous system diseases, with encouraging results in Alzheimer’s, Parkinson’s, and Rett... 
Via Talk Markets
Tesla To $205? Here Are 10 Other Price Target Changes For Tuesday
Goldman Sachs cut Tesla, Inc. (NASDAQ: TSLA) price target from $235 to $205. Goldman Sachs analyst Mark Delaney maintained a Buy rating on the stock. Tesla shares fell 2.6% to $119.93 in pre-market... 
Via Benzinga
Analyzing Anavex Life Sciences's Short Interest
Anavex Life Sciences's (NASDAQ:AVXL) short percent of float has risen 17.06% since its last report. The company recently reported that it has 11.91 million shares sold short, which is 15.71% of all... 
Via Benzinga
Anavex Life Sciences Stock Could 5x Before 2025 -- Here's Why
The biotech will first need to assuage the concerns of experts by elaborating on its latest clinical trial data. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.